No Cancer Recurrence with Biologic DMARDs in RA

A prospective Danish rheumatoid arthritis (RA) registry study look at the risk of recurrence when a biological disease-modifying antirheumatic drugs (bDMARDs) was ued in patients with a a prior solid cancer (in remission) and found no increased cancer recurrence risk. 

The DANBIO ationwide registry examined RA patients with solid cancers in remission (breast, colorectal, melanoma, bladder, endometrial and lung) who were treated with either a bDMARD or a csDMARD.  The specifically examined the influence of certain therapies: (1) any bDMARD, (2) tumour necrosis factor inhibitors (TNFi) and (3) rituximab. 

A total of 720 RA patients with prior solid cancers were studied: 170 any bDMARD, 81 TNFi, 99 rituximab and 651 csDMARD initiators. They found no statistically significant increased risk for cancer recurrence with:

  • Any bDMARD HR 0.92 (95% CI 0.38 to 1.73)

  • TNFi NR 1.10 (95% CI 0.21 to 3.16) 

  • Rituximab HR 0.94 (95% CI 0.32 to 2.11). 

Also, no increased risk was seen for breast cancer recurrence. These studies show advantage of one bDMARD over another in those with a prior solid tumor.

Continue Reading
Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
×